The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Lee, Carol M ^a   Tannock, Ian F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADENOSQUAMOUS CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BINDING; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; FEMALE; HUMAN; HUMAN CELL; HYPOXEMIA; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SINGLE DRUG DOSE; SOLID TUMOR; TISSUE DISTRIBUTION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; WILD TYPE; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; CELL HYPOXIA; GENETIC TRANSFECTION; GENETICS; HALF LIFE TIME; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; NUDE MOUSE; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CELL LINE, TUMOR; FEMALE; HALF-LIFE; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TISSUE DISTRIBUTION; TRANSFECTION;

EID: 77953009791     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-255     Document Type: Article

References (50)

1. Roskoski R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochemical and biophysical research communications 2004, 319(1):1-11. 10.1016/j.bbrc.2004.04.150, 15158434.
2. Weiss A, Schlessinger J. Switching signals on or off by receptor dimerization. Cell 1998, 94(3):277-280. 10.1016/S0092-8674(00)81469-5, 9708728.
3. DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D, Thor AD. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 2005, 23(6):1152-1160. 10.1200/JCO.2005.09.055, 15718311.
4. O'Dwyer PJ, Benson AB. Epidermal growth factor receptor-targeted therapy in colorectal cancer. Seminars in oncology 2002, 29(5 Suppl 14):10-17. 10.1053/sonc.2002.35643, 12422309.
5. Herbst RS, Hong WK. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Seminars in oncology 2002, 29(5 Suppl 14):18-30. 10.1053/sonc.2002.35644, 12422310.
6. Lager DJ, Slagel DD, Palechek PL. The expression of epidermal growth factor receptor and transforming growth factor alpha in renal cell carcinoma. Mod Pathol 1994, 7(5):544-548.
7. Berger MS, Gullick WJ, Greenfield C, Evans S, Addis BJ, Waterfield MD. Epidermal growth factor receptors in lung tumours. The Journal of pathology 1987, 152(4):297-307. 10.1002/path.1711520408, 3668732.
8. Hirsch FR, Scagliotti GV, Langer CJ, Varella-Garcia M, Franklin WA. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung cancer (Amsterdam, Netherlands) 2003, 41(Suppl 1):S29-42.
9. Xiong HQ, Abbruzzese JL. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Seminars in oncology 2002, 29(5 Suppl 14):31-37. 10.1053/sonc.2002.35645, 12422311.
10. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002, 8(11):3438-3444.
11. Itakura Y, Sasano H, Shiga C, Furukawa Y, Shiga K, Mori S, Nagura H. Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 1994, 74(3):795-804. 10.1002/1097-0142(19940801)74:3<795::AID-CNCR2820740303>3.0.CO;2-I, 8039107.
12. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Critical reviews in oncology/hematology 1995, 19(3):183-232. 10.1016/1040-8428(94)00144-I, 7612182.
13. Goldberg RM. Cetuximab. Nature reviews 2005, (Suppl):S10-11.
14. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995, 1(11):1311-1318.
15. Harris M. Monoclonal antibodies as therapeutic agents for cancer. The lancet oncology 2004, 5(5):292-302. 10.1016/S1470-2045(04)01467-6, 15120666.
16. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Molecular biology & medicine 1983, 1(5):511-529.
17. Leyland-Jones B. Trastuzumab: hopes and realities. The lancet oncology 2002, 3(3):137-144. 10.1016/S1470-2045(02)00676-9, 11902499.
18. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002, 94(5):1593-1611. 10.1002/cncr.10372, 11920518.
19. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 1997, 3(12 Pt 2):2703-2707.
20. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer research 2001, 61(12):4744-4749.
21. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. The New England journal of medicine 2004, 351(4):337-345. 10.1056/NEJMoa033025, 15269313.
22. Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. The New England journal of medicine 2007, 357(1):39-51. 10.1056/NEJMra043186, 17611206.
23. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006, 6(8):583-592. 10.1038/nrc1893, 16862189.
24. Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 2005, 11(24 Pt 1):8782-8788. 10.1158/1078-0432.CCR-05-1664, 16361566.
25. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. Journal of the National Cancer Institute 2007, 99(19):1441-1454. 10.1093/jnci/djm135, 17895480.
26. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer research 1987, 47(12):3039-3051.
27. Jain RK. Barriers to drug delivery in solid tumors. Scientific American 1994, 271(1):58-65. 10.1038/scientificamerican0794-58, 8066425.
28. Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends in pharmacological sciences 2008, 29(2):57-61. 2820301, 18179828.
29. Evans SM, Hahn S, Pook DR, Jenkins WT, Chalian AA, Zhang P, Stevens C, Weber R, Weinstein G, Benjamin I, et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer research 2000, 60(7):2018-2024.
30. Lord EM, Harwell L, Koch CJ. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer research 1993, 53(23):5721-5726.
31. du Manoir JM, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A, Hicklin DJ, Emmenegger U, Kerbel RS. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 2006, 12(3 Pt 1):904-916. 10.1158/1078-0432.CCR-05-1109, 16467105.
32. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. The New England journal of medicine 2006, 354(8):809-820. 10.1056/NEJMoa053028, 16495393.
33. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. The New England journal of medicine 2005, 353(16):1659-1672. 10.1056/NEJMoa052306, 16236737.
34. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. The New England journal of medicine 2005, 353(16):1673-1684. 10.1056/NEJMoa052122, 16236738.
35. Sutherland R, Buchegger F, Schreyer M, Vacca A, Mach JP. Penetration and binding of radiolabeled anti-carcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular tumor spheroids. Cancer research 1987, 47(6):1627-1633.
36. Gustafson DL, Rastatter JC, Colombo T, Long ME. Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model. Journal of pharmaceutical sciences 2002, 91(6):1488-1501. 10.1002/jps.10161, 12115848.
37. Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 2005, 56(4):361-369. 10.1007/s00280-005-1026-z, 15868146.
38. Fracasso PM, Burris H, Arquette MA, Govindan R, Gao F, Wright LP, Goodner SA, Greco FA, Jones SF, Willcut N, et al. A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res 2007, 13(3):986-993. 10.1158/1078-0432.CCR-06-1542, 17289894.
39. Luo FR, Yang Z, Dong H, Camuso A, McGlinchey K, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S, et al. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. Cancer Chemother Pharmacol 2005, 56(5):455-464. 10.1007/s00280-005-1022-3, 15947929.
40. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007, 18(1):23-28. 10.1097/01.cad.0000236313.50833.ee, 17159499.
41. Tan AR, Moore DF, Hidalgo M, Doroshow JH, Poplin EA, Goodin S, Mauro D, Rubin EH. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res 2006, 12(21):6517-6522. 10.1158/1078-0432.CCR-06-0705, 17065274.
42. Tokuda Y, Watanabe T, Omuro Y, Ando M, Katsumata N, Okumura A, Ohta M, Fujii H, Sasaki Y, Niwa T, et al. Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Br J Cancer 1999, 81(8):1419-1425. 10.1038/sj.bjc.6690343, 2362960, 10604742.
43. Waterhouse DN, Denyssevych T, Hudon N, Chia S, Gelmon KA, Bally MB. Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels. Pharm Res 2005, 22(6):915-922. 10.1007/s11095-005-4586-z, 15948035.
44. Blumenthal RD, Osorio L, Ochakovskaya R, Ying Z, Goldenberg DM. Regulation of tumour drug delivery by blood flow chronobiology. Eur J Cancer 2000, 36(14):1876-1884. 10.1016/S0959-8049(00)00177-5, 10974637.
45. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer research 2001, 61(12):4750-4755.
46. Jones PL, Gallagher BM, Sands H. Autoradiographic analysis of monoclonal antibody distribution in human colon and breast tumor xenografts. Cancer Immunol Immunother 1986, 22(2):139-143. 10.1007/BF00199128, 3719593.
47. Saga T, Neumann RD, Heya T, Sato J, Kinuya S, Le N, Paik CH, Weinstein JN. Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proceedings of the National Academy of Sciences of the United States of America 1995, 92(19):8999-9003. 10.1073/pnas.92.19.8999, 41095, 7568060.
48. Steffens MG, Oosterwijk-Wakka JC, Zegwaart-Hagemeier NE, Boerman OC, Debruyne FM, Corstens FH, Oosterwijk E. Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250. Anticancer research 1999, 19(2A):1197-1200.
49. Dennis MS, Jin H, Dugger D, Yang R, McFarland L, Ogasawara A, Williams S, Cole MJ, Ross S, Schwall R. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer research 2007, 67(1):254-261. 10.1158/0008-5472.CAN-06-2531, 17210705.
50. Baker JH, Lindquist KE, Huxham LA, Kyle AH, Sy JT, Minchinton AI. Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin Cancer Res 2008, 14(7):2171-2179. 10.1158/1078-0432.CCR-07-4465, 18381959.